Navigation Links
Ampio Responds to Levi & Korsinsky, LLP Press release/solicitation
Date:11/19/2013

GREENWOOD VILLAGE, Colo., Nov. 19, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) CEO, Michael Macaluso, remarked "We are not aware of any basis for an investigation of Ampio. We note that the law firm's press release/solicitation does not contain any facts whatsoever that would explain why they are conducting an investigation.  Any objective review of Ampio's promising clinical trial results and subsequent stock performance achieved over the past year will conclude that the company is performing well.  Consequently we believe this provocative solicitation is not intended to benefit shareholders and we encourage all interested parties to form their own conclusions about the motivation behind this law firm's actions."

(Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO)

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.

Forward Looking Statements

Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking st
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
2. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
3. Champions Oncology Reports Financial Results for the Year Ended April 30, 2012
4. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
5. Amarantus Appoints Super Bowl Champion Toi Cook to Board of Advisors to Advance TBI Program
6. CSL Behring Partners with Pro Supercross Racer Carl Schlacht to Encourage Those with Primary Immunodeficiency to be a "ChamPIon"
7. Champions Oncology Reports Financial Results for the Quarter Ended October 31, 2012
8. North Carolina A&T State University Crowned Champion in $100,000 ACC Clean Energy Challenge
9. Ampio Pharmaceuticals Announces Participation at the UBS Global Healthcare Conference
10. GenoSpace Founder and CEO Receives "Champions of Change" Award from White House
11. Olympic Champion and Health and Fitness Advocate Dara Torres Partners with Vestiage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... 31, 2014 The Global and ... and in-depth study on the current state of ... China. , The report provides a basic overview ... chain structure. Global market analysis and Chinese domestic ... history, developments, trends and competitive landscape of the ...
(Date:8/29/2014)... 2014 Pittcon is pleased to announce ... Koichiro Matsuda, Horiba Scientific, have organized a session on ... JASIS , Asia’s largest analytical and scientific instruments ... Messe, Japan. , The four speakers in this ... Single Molecules to Single Cells” will present their use ...
(Date:8/29/2014)... A major challenge before new biotechnology ... realm of Boston-Cambridge, is gaining visibility that can lead ... the Director of Boston’s Adult Stem Cell Technology Center, ... visibility of his company an important priority since he ... to a social media marketing campaign launched ...
(Date:8/28/2014)... 28, 2014 “This kit has an improved ... from 0 to 150 ppb,” said Mark Tess, PhD, Mycotoxin ... benefit to plant owners and USDA-GIPSA inspection agencies that have ... Testing can take place in a matter of minutes with ... plant test the feed and grain before accepting it, but ...
Breaking Biology Technology:Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4
... 11 AtriCure, Inc.,(Nasdaq: ATRC ), a ... surgical,ablation products, today announced that the first patient ... Richard Kaplon, a,well-known cardiac surgeon, performed the procedure ... purpose of the ABLATE clinical trial is to ...
... 11, Bayer HealthCare affiliate MEDRAD, Inc., Warrendale, PA ... ), announced today that,they have entered into a ... Possis Medical in a cash tender offer for ... of approximately US-Dollar 361,million. The offer price represents ...
... Ltd. announced that the,quantitative analysis of Replikin Count(TM) ... H5N1 cycle is over. Sporadic outbreaks may,continue, but ... expected to subside - until the next rapid ... begins., 140,000 virus protein sequences were analyzed ...
Cached Biology Technology:AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation 2AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation 3AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation 4Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 2Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 3Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 4Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 5Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 6FluForecast(R) Replikin Count(TM) Predicts That the H5N1 Cycle Which Began in 1996 Is Now Over 2
(Date:9/1/2014)... The week-long discussions and decisions of the Nomenclature Section ... Melbourne, Australia in July 2011. This meeting is held ... premier experts on the rules for naming algae, fungi ... rule book for naming the organisms they study. This ... Code of Nomenclature for algae, fungi, and plants, which ...
(Date:8/31/2014)... bacteria C. diff , that causes diarrhoea, temperature ... at the University of Leicester. , Using a mass ... possible to identify the unique ,smell, of C. ... the condition., What is more, the Leicester team say ... the disease simply from their smell a chemical ...
(Date:8/31/2014)... the last 19 years reveals that fresh water from melting ... to rise by 2cm more than the global average of ... rapid rise in sea-level by studying satellite scans of a ... , The melting of the Antarctic ice sheet and ... of around 350 gigatonnes of freshwater to the surrounding ocean. ...
Breaking Biology News(10 mins):Week-long meeting on naming algae, fungi, and plants recorded for posterity 2Scientists develop 'electronic nose' for rapid detection of C. diff infection 2
... been inspiring debate across the scientific community since the ... wider discussion about open access publishing has advanced to ... its first few articles (please see http://f1000research.com/articles ). ... further articles will be published on the current consultation ...
... have long known that the body rids itself of excess ... liver and excreting them through the liver,s bile. However, a ... 22 in PLoS ONE suggests that when this ... A molecule sequesters only that mineral and routes it from ...
... new genetic mutation that causes familial amyotrophic lateral sclerosis ... Gehrig,s Disease, has been identified by a team of ... Medical School (UMMS). Mutations to the profilin (PFN1) gene, ... nerve cell axons, is estimated to account for one ...
Cached Biology News:First articles now live on F1000 Research 2First articles now live on F1000 Research 3Copper's previously unknown exit strategy 2Copper's previously unknown exit strategy 3UMMS researchers isolate gene mutations in patients with inherited amyotrophic lateral sclerosis 2UMMS researchers isolate gene mutations in patients with inherited amyotrophic lateral sclerosis 3